Von Willebrand disease pathophysiology

Revision as of 16:28, 29 August 2018 by Nazia Fuad (talk | contribs)
Jump to navigation Jump to search

Von Willebrand disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Von Willebrand disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Von Willebrand disease pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Von Willebrand disease pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Von Willebrand disease pathophysiology

on Von Willebrand disease pathophysiology

Von Willebrand disease pathophysiology in the news

Blogs on Von Willebrand disease pathophysiology

Directions to Hospitals Treating Von Willebrand disease

Risk calculators and risk factors for Von Willebrand disease pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Prince Tano Djan, BSc, MBChB [2] Nazia Fuad M.D.

Overview

Pathophysiology

Physiology

Von Willebrand factor (vWF)

The normal physiology of von Willebrand’s factor can be understood as follows:[1]

Structure

These monomer contains a number of specific domains with a distinguishing function.

Function

Pathogenesis

von Willebrand disease is due to an abnormality, either quantitative or qualitative, of the von Willebrand factor[2]

Pathogenetic mechanisms of inherited VWD

VWD subtype Pathogenetic mechanisms
Type 1 VWD 65% have VWF mutations Partial quantitative deficiency of VWF
70% of VWF variants are missense substitutions affecting VWF trafficking, storage, secretion, and clearance
Transcription and splicing VWF mutations
Type 2A VWD Mutations in D1/D2/D′D3 assemblies, A2 and CTCK domains Loss of high-molecular-weight multimers (HMWMs)
Interference with HMW multimer formation, storage, and secretion
Increased ADAMTS13 proteolysis
Type 2B VWD Mutations in A1 domain The increase in binding of larger VWF multimers to platelet GP Ib results in sequestration of the platelets and VWF resulting in Thrombocytopenia
Excessive binding to GPIb glycoprotein Ib
Type 2M VWD Mutations in A1 and A3 domains Qualitative variants with decreased binding of VWF to GP Ib, resulting in decreased platelet adhesion
Diminished binding to GPIbα glycoprotein Ib (A1 domain) or collagen (A3 domain)
Type 2N VWD Missense variants in D′D3 assembly Qualitative variants with remarkably decreased affinity for FVIII
Reduced FVIII binding
Type 3 VWD VWF mutations found in 85%-90% of cases Produces null phenotype or the VWF that is not secreted.
VWF deletions, nonsense, splice site, and missense mutations

Pathogenetic mechanisms of acquired VWD

  • Acquired VWD is associated with other diseases resulting from different pathological processes. These pathological processes include:


Genetics

Von Willebrand disease types 1 and 2 (except type 2N which is inherited recessively) are inherited as autosomal dominant traits and type 3 is inherited as autosomal recessive. The diagram below illustrates autosomal dominant inheritance.

von Willebrand disease
von Willebrand disease types I and II are inherited in an autosomal dominant pattern.

Associated conditions

Acquired conditions associated with Von Willebrand disease include the following:[13][14][3][4][5][6][7]

Heart-related conditions

Malignant diseases

Drugs and other agents

Autoimmune disorders

Other disorders

References

  1. Peyvandi F, Garagiola I, Baronciani L (May 2011). "Role of von Willebrand factor in the haemostasis". Blood Transfus. 9 Suppl 2: s3–8. doi:10.2450/2011.002S. PMC 3159913. PMID 21839029.
  2. Lillicrap D (November 2013). "von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy". Blood. 122 (23): 3735–40. doi:10.1182/blood-2013-06-498303. PMC 3952678. PMID 24065240.
  3. 3.0 3.1 Franchini M, Lippi G (2007). "Acquired von Willebrand syndrome: an update". Am J Hematol. 82 (5): 368–75. doi:10.1002/ajh.20830. PMID 17133419.
  4. 4.0 4.1 Tiede A, Rand JH, Budde U, Ganser A, Federici AB (2011). "How I treat the acquired von Willebrand syndrome". Blood. 117 (25): 6777–85. doi:10.1182/blood-2010-11-297580. PMID 21540459.
  5. 5.0 5.1 Kumar S, Pruthi RK, Nichols WL (2002). "Acquired von Willebrand disease". Mayo Clin Proc. 77 (2): 181–7. doi:10.4065/77.2.181. PMID 11838652.
  6. 6.0 6.1 Veyradier A, Jenkins CS, Fressinaud E, Meyer D (2000). "Acquired von Willebrand syndrome: from pathophysiology to management". Thromb Haemost. 84 (2): 175–82. PMID 10959686.
  7. 7.0 7.1 Federici AB, Rand JH, Bucciarelli P, Budde U, van Genderen PJ, Mohri H; et al. (2000). "Acquired von Willebrand syndrome: data from an international registry". Thromb Haemost. 84 (2): 345–9. PMID 10959711.
  8. Ng et al. Diagnostic Approach to von Willebrand Disease. Blood 2015; 125(13): 2029-2037.
  9. Blomback et al. Von Willebrand Disease Biology Hemophilia 2012; 18: 141-147.
  10. Favarolo et al. Von Willebrand Disease and Platelet Disorders. Hemophilia 2014; 20: 59-64.
  11. van Genderen PJ, Vink T, Michiels JJ, van 't Veer MB, Sixma JJ, van Vliet HH (1994). "Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen". Blood. 84 (10): 3378–84. PMID 7949092.
  12. Handin RI, Martin V, Moloney WC (1976). "Antibody-induced von Willebrand's disease: a newly defined inhibitor syndrome". Blood. 48 (3): 393–405. PMID 1085186.
  13. Simone JV, Cornet JA, Abildgaard CF (1968). "Acquired von Willebrand's syndrome in systemic lupus erythematosus". Blood. 31 (6): 806–12. PMID 4172730.
  14. Wautier JL, Levy-Toledano S, Caen JP (1976). "Acquired von Willebrand's syndrome and thrombopathy in a patient with chronic lymphocytic leukaemia". Scand J Haematol. 16 (2): 128–34. PMID 1083062.

Template:WH Template:WS